STW5 (Iberogast) vs placebo
Adverse events Assessed clinically · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
- RR 0.92 [0.52, 1.64]4 studies · 786 participantsLow